Full Spectrum vs Broad Spectrum vs Isolate: What the Labels Mean
Product Types
69% Mislabeled
A 2017 JAMA study found 69 percent of CBD products sold online were mislabeled, making the distinction between full spectrum, broad spectrum, and isolate a matter of what you are actually putting in your body.
Bonn-Miller et al., JAMA, 2017
Bonn-Miller et al., JAMA, 2017
View as imageIf you have tried to buy a CBD product in the last few years, you have faced a choice that the label presents as simple but the science makes complicated: full spectrum, broad spectrum, or isolate. These terms appear on tinctures, capsules, gummies, topicals, and vape products, and they describe fundamentally different approaches to extracting and processing cannabis compounds.
The distinction matters. It affects what you are putting in your body, whether you might fail a drug test, how much you should expect to pay, and how the product might affect you. This article explains what each term means, how the products are made, and what the evidence says about which type works best.
Key Takeaways
- Full spectrum extracts keep everything the plant makes — all cannabinoids, terpenes, and flavonoids — including up to 0.3% THC in hemp-derived products
- Broad spectrum goes through extra processing to strip out the THC while trying to keep everything else, though some minor cannabinoids and terpenes can get lost along the way
- Isolate is the purest form — typically 99%+ of a single cannabinoid like CBD or CBG — with every other plant compound removed
- Drug testing is where the choice really matters: full spectrum carries a real risk of a positive THC test, broad spectrum carries a smaller but nonzero risk, and isolate is the safest bet
- The claim that full spectrum always works better than isolate is based on the entourage effect hypothesis, which has some lab support but limited proof in actual humans
- A 2017 study by Bonn-Miller et al. in JAMA found that 69 percent of CBD products sold online were mislabeled — some had THC when they said they didn't — so always check the third-party certificate of analysis no matter which type you buy
Full Spectrum: The Whole Profile
Full Spectrum vs Broad Spectrum vs Isolate
Label accuracy warning: A 2017 JAMA study found 69% of CBD products sold online were mislabeled — some had THC when they claimed not to. Always check the third-party certificate of analysis.
Full spectrum extracts attempt to capture the complete chemical profile of the cannabis plant. This includes the primary cannabinoids (CBD and THC), minor cannabinoids (CBG, CBN, CBC, and others), terpenes, flavonoids, and other plant compounds.
For hemp-derived products sold legally under the 2018 Farm Bill, full spectrum means the extract contains THC at or below 0.3% by dry weight. That is a small amount, well below the threshold for producing intoxication in most people, but it is not zero. In a high-dose CBD product, even 0.3% THC can add up to a few milligrams per serving.
The extraction process for full spectrum products typically uses CO2 or ethanol. Supercritical CO2 extraction is considered the gold standard because it can pull a wide range of compounds from the plant at different pressures and temperatures without leaving toxic solvent residues. Ethanol extraction is simpler and cheaper but may pull unwanted compounds like chlorophyll, requiring additional refinement.
The key feature of full spectrum is that the natural ratio of compounds is largely preserved. If the source plant had a particular balance of CBD, CBG, CBC, and terpenes, the extract should reflect that. This is the product type most associated with the entourage effect hypothesis, the idea that these compounds work better together than in isolation. For a detailed examination of that hypothesis, see the entourage effect.
Broad Spectrum: THC Removed
Broad spectrum is essentially full spectrum with the THC removed. The extract starts with the full range of cannabinoids and terpenes, then undergoes additional processing to eliminate THC while retaining everything else.
There are several methods for removing THC from an extract. Chromatography is the most precise, using chemical separation techniques to isolate and remove THC molecules. Distillation can also be used, taking advantage of the different boiling points of various cannabinoids. Some manufacturers start with a CBD isolate and then add back specific cannabinoids and terpenes to create a broad spectrum profile, though this is technically a reconstructed product rather than a naturally broad spectrum one.
The challenge with THC removal is precision. Removing one specific cannabinoid without disturbing others is difficult. Some minor cannabinoids and terpenes may be lost or reduced during the process. The final product may not have the same complete profile as a full spectrum extract, even setting aside the THC removal.
A critical point: "THC-free" on a broad spectrum label does not always mean zero THC. It typically means THC below the detection limit of the test used, which varies by laboratory. Trace amounts of THC may still be present. Most broad spectrum products specify "non-detectable THC" or "THC-free" based on a specific testing threshold, often 0.01% or lower.
Isolate: One Compound, Maximum Purity
Isolate is the simplest product conceptually. It is a single cannabinoid purified to 99% or higher, with all other plant compounds removed. CBD isolate is the most common, but CBG isolate and other single-cannabinoid isolates are also available.
The production process involves extracting the full plant material, then using winterization, distillation, and crystallization to strip away everything except the target cannabinoid. The result is usually a white, crystalline powder that is odorless and tasteless.
Isolate has several practical advantages. Dosing is precise because you know exactly how many milligrams of the active compound you are taking. There is no risk of THC exposure. The product is consistent across batches. And it is typically the least expensive option per milligram of active cannabinoid, because the manufacturing process, while multi-step, produces a standardized commodity product.
The most notable example of a CBD isolate in clinical use is Epidiolex, the FDA-approved medication for Dravet syndrome and Lennox-Gastaut syndrome. Epidiolex is purified CBD with no other cannabinoids or terpenes. Its clinical efficacy demonstrates that isolated CBD can produce meaningful therapeutic effects without the entourage of other cannabis compounds.
Drug Testing: The Most Practical Difference
For many people, the choice between these three product types comes down to drug testing. Standard urine drug screens test for THC metabolites (specifically 11-nor-9-carboxy-THC), not CBD or other cannabinoids.
Full spectrum products carry real drug test risk. Even at 0.3% THC, regular use of high-dose full spectrum CBD products can accumulate enough THC metabolites to trigger a positive test. A 2019 study published in JAMA found that some commercial CBD products contained significantly more THC than their labels indicated. If your employment, legal status, or athletic eligibility depends on passing a drug test, full spectrum products are a gamble.
Broad spectrum products carry lower but nonzero risk. If the THC removal process was incomplete, or if the product was mislabeled, trace THC could still be present. The risk is substantially lower than full spectrum, but it is not eliminated.
Isolate carries the lowest risk. A properly manufactured and tested CBD isolate should contain no THC. However, third-party testing is still advisable, because the cannabinoid market has documented quality control issues. Bonn-Miller and colleagues published a 2017 study in JAMA finding that 69% of CBD products sold online were mislabeled, with some containing THC when they claimed not to.
If you are subject to drug testing, isolate is the safest choice. If you choose broad spectrum, verify THC content with a current certificate of analysis from a third-party lab.
Which Has the Most Evidence
This is where the conversation gets complicated, because the answer depends on what you mean by evidence.
CBD isolate has the most rigorous clinical evidence for a specific condition (epilepsy), thanks to the Epidiolex trials. These were large, randomized, placebo-controlled studies, the gold standard of clinical research.
Full spectrum products have more anecdotal and observational support for a broader range of uses, including pain, anxiety, and sleep. Some preclinical studies suggest that full-plant extracts are effective at lower doses than isolates, a concept supported by a 2015 study by Gallily and colleagues at the Hebrew University of Jerusalem that found full spectrum CBD extract had a dose-response curve that continued improving at higher doses, while CBD isolate had a bell-shaped curve where efficacy decreased at higher doses. This study was conducted in mice, not humans.
Broad spectrum has the least dedicated research. Most studies use either whole-plant extracts or pure isolates. Broad spectrum is a commercial category more than a research category, and very few clinical trials have specifically tested broad spectrum products.
Price Differences
In general, isolate is the least expensive per milligram of active cannabinoid. The manufacturing process is well-established, the product is a commodity, and there is no need to preserve delicate terpene and minor cannabinoid profiles.
Full spectrum products typically cost more because the extraction process must be more carefully controlled to preserve the full chemical profile. CO2 extraction equipment is expensive, and maintaining terpene integrity requires lower temperatures and more precise conditions.
Broad spectrum products are often the most expensive, because they require the full spectrum extraction process plus additional THC removal steps. The extra processing adds cost.
Whether the premium for full spectrum or broad spectrum products is justified depends on whether those additional compounds actually improve outcomes for you. Given the current state of the evidence, that is an individual determination rather than a settled scientific question.
How to Choose Based on Your Needs
Choose full spectrum if you are not subject to drug testing, you want the broadest range of cannabis compounds, you are comfortable with trace THC, and the entourage effect hypothesis appeals to you. Full spectrum is the closest to the natural plant profile.
Choose broad spectrum if you want a range of cannabinoids and terpenes but need to avoid THC for drug testing, legal, or personal reasons. Verify the THC content with third-party lab results.
Choose isolate if you need maximum control over what you are consuming, you are subject to drug testing, you want the most affordable option per milligram, or you want to know with certainty that you are taking only one specific cannabinoid.
Choose based on how you respond. Some people notice a meaningful difference between full spectrum and isolate. Others do not. Your biology, the condition you are addressing, and the doses you are using all affect this. If you have tried isolate and it works well, there may be no reason to pay more for full spectrum. If isolate has not worked, a full spectrum product is worth trying.
Reading Labels Critically
Not all products are accurately labeled. The cannabinoid market has known quality control issues, and terms like "full spectrum" and "broad spectrum" are not legally defined with the precision you might expect.
Look for a current certificate of analysis (COA) from a third-party laboratory. This should list the concentrations of major and minor cannabinoids and confirm that THC content matches the product's claims. Look for terpene profiles if the product claims to be full or broad spectrum. If a product claims to be full spectrum but the COA shows only CBD with no minor cannabinoids or terpenes, the label may be misleading.
Check that the lab is ISO 17025 accredited. Look at the batch number on the COA and make sure it matches the product. If a company does not make COAs easily accessible, that is a red flag.
The Bottom Line
Full spectrum, broad spectrum, and isolate describe real differences in product composition that affect drug test risk, price, and potentially efficacy. The strongest clinical evidence exists for isolate (via Epidiolex), while the entourage effect hypothesis provides a theoretical basis for full spectrum products that has preclinical but limited clinical support.
The honest answer about which is best is that it depends on your circumstances. Drug testing considerations, your response to different products, your budget, and your comfort with uncertainty all factor in. The labels give you a starting point. Third-party lab testing gives you verification. And your own experience over time gives you the most personally relevant data.
The Bottom Line
Practical comparison of three cannabis extract categories with evidence-based guidance. Full spectrum: retains all cannabinoids (CBD, THC ≤0.3%, CBG, CBN, CBC), terpenes, flavonoids; CO2 or ethanol extraction; preserves natural compound ratios; associated with entourage effect hypothesis; carries real drug test risk from accumulated THC metabolites. Broad spectrum: full spectrum with THC removed via chromatography or distillation; "THC-free" means below detection limit (often 0.01%), not necessarily zero; some minor cannabinoids/terpenes lost during THC removal; lower but nonzero drug test risk; reconstructed products (isolate + added compounds) sometimes sold as broad spectrum. Isolate: 99%+ pure single cannabinoid (usually CBD); white crystalline powder; precise dosing, no THC risk, lowest cost per mg; Epidiolex (FDA-approved CBD isolate) proves isolates can be clinically effective. Drug testing hierarchy: full spectrum (real risk) > broad spectrum (lower but nonzero) > isolate (lowest). Evidence: isolate has strongest clinical evidence via Epidiolex trials; full spectrum has more anecdotal/preclinical support including 2015 Gallily dose-response study (mice); broad spectrum has least dedicated research. Quality concerns: 2017 Bonn-Miller JAMA — 69% of online CBD products mislabeled; 2019 JAMA study found some products had more THC than labeled. Always verify with third-party COA from ISO 17025 accredited lab.
Frequently Asked Questions
Sources & References
- 1RTHC-08288·Gorbenko, Andriy A et al. (2026). “CBD May Not Have Anti-Seizure Properties On Its Own.” Clinical pharmacology and therapeutics.Study breakdown →PubMed →↩
- 2RTHC-00098·Malfait, A M et al. (2000). “CBD Blocked Arthritis Progression in Mice When Given After Symptoms Started, Published in PNAS.” Proceedings of the National Academy of Sciences of the United States of America.Study breakdown →PubMed →↩
- 3RTHC-00157·Berman, Jonathan S et al. (2004). “Cannabis Sprays Reduced Nerve Pain from Brachial Plexus Injury.” Pain.Study breakdown →PubMed →↩
- 4RTHC-00171·Nicholson, Anthony N et al. (2004). “How THC and CBD Affect Sleep: A Controlled Study with Brain Wave Monitoring.” Journal of clinical psychopharmacology.Study breakdown →PubMed →↩
- 5RTHC-00150·Wade, Derick T et al. (2003). “Cannabis Extracts Helped Neurological Pain and Symptoms That Standard Treatments Could Not.” Clinical rehabilitation.Study breakdown →PubMed →↩
- 6RTHC-00124·Killestein, J et al. (2002). “THC and Cannabis Extract Did Not Reduce Spasticity in This MS Trial.” Neurology.Study breakdown →PubMed →↩
- 7RTHC-00039·Consroe, P et al. (1991). “High-Dose CBD Was Neither Effective Nor Toxic for Huntington's Disease in a Controlled Trial.” Pharmacology.Study breakdown →PubMed →↩
- 8RTHC-08071·Alexander, Stephen P H (2026). “Mapping How 100+ Cannabis Plant Compounds Interact with the Body.” Current topics in behavioral neurosciences.Study breakdown →PubMed →↩
Research Behind This Article
Showing the 8 most relevant studies from our research database.
New approaches and challenges to targeting the endocannabinoid system.
Di Marzo, Vincenzo · 2018
The classical endocannabinoid system — two receptors (CB1 and CB2), two endocannabinoids (anandamide and 2-AG), and a handful of enzymes — is part of a much larger network that Di Marzo termed the 'endocannabinoidome.' This expanded system includes over 20 receptors (including GPR55, TRPV1, PPARs), dozens of lipid mediators chemically related to endocannabinoids (like PEA, OEA, and oleamide), and the metabolic enzymes that produce and degrade them.
Plant cannabinoids: a neglected pharmacological treasure trove.
Mechoulam, Raphael · 2005
Writing four decades after isolating THC, Raphael Mechoulam argued that most of the ~100 cannabinoids identified in Cannabis sativa had never been properly evaluated pharmacologically.
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis.
Malfait, A M · 2000
Using two mouse models of rheumatoid arthritis, researchers tested CBD given after clinical symptoms had already appeared, mimicking how patients would actually use the treatment. CBD effectively blocked arthritis progression in both acute and chronic relapsing models.
Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.
Gorbenko, Andriy A · 2026
Single doses of 30 mg and 700 mg CBD had no significant effects on single-pulse or paired-pulse TMS-EMG measures of cortical excitability, nor on validated CNS sedation tests, compared to placebo — suggesting CBD may lack intrinsic anti-epileptic and sedative properties..
Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial.
Berman, Jonathan S · 2004
In 48 patients with chronic nerve pain from brachial plexus root avulsion, both Sativex (THC:CBD approximately 1:1) and a THC-only extract delivered by oral spray produced statistically significant improvements in pain severity compared to placebo during two-week treatment periods.
Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults.
Nicholson, Anthony N · 2004
In 8 healthy volunteers given sublingual cannabis extracts before sleep, 15 mg THC alone had no effect on nocturnal sleep architecture but produced next-day sedation, impaired memory, and reduced sleep latency (indicating increased sleepiness).
A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.
Wade, Derick T · 2003
In 24 patients with neurological conditions (18 MS, 4 spinal cord injury, 2 other) whose symptoms had not responded to standard treatments, sublingual cannabis extracts produced significant pain relief.
Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
Killestein, J · 2002
In this randomized, double-blind, placebo-controlled crossover study, 16 patients with severe multiple sclerosis spasticity received oral THC, cannabis plant extract, and placebo in different periods.